slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 83,671-83,700
Pages 3,225
Rows per page 30
Component
83,671-83,700 of 96,741
32
Includes detailed footnotes regarding transaction assumptions and currency conversion.Allego | SPAC Presentation Deck | 37 slides · Allego
Pitch deck Investment bank 1 hit
34
Includes a timeline-style indicator for 'Estimated First Year EBITDA Positive' at the bottom.Allego | SPAC Presentation Deck | 37 slides · Allego
Pitch deck Investment bank 1 hit
03
The slide highlights a 62% year-over-year decline in FCF despite a 16% growth in operating cash flow, as noted in the footnotes.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
04
The slide emphasizes a significant drop in this specific non-GAAP metric, framed as part of a long-term optimization goal.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
05
The slide uses a specific, highly qualified non-GAAP metric to track cash flow performance.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
06
The chart shows minimal change in share counts over the five quarters.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
07
The slide includes a footnote explaining the F/X adjustment methodology.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
08
The bar chart shows growth from Q2 2020 to Q2 2021. The pie chart shows the composition of sales by North America, International, and AWS.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
09
The chart shows a 32% Y/Y growth, likely comparing Q2 2020 to Q2 2021.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
10
The chart highlights a 76% year-over-year growth in operating income.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
11
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
12
The chart highlights a 123% year-over-year growth.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
10
The slide uses a process-like flow to connect disease states to specific clinical data and future opportunities.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
11
The slide uses a comparison matrix structure to justify the expansion of a clinical franchise into a new indication.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
15
The slide uses a Venn-like diagram to connect three core pillars to six specific business achievements.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
17
The slide uses a numbered list to explain a biological process (pinocytosis, binding, rescue, release) mapped to a visual diagram.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
18
The slide uses a numbered process/comparison flow to contrast binding modes.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
20
The slide uses a causal flow diagram to explain the mechanism of action.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
22
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
29
The slide illustrates the diversity of autoantibodies in myositis patients, supporting the thesis that a broad-acting therapy like Efgartigimod is effective.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
32
The chart is a Kaplan-Meier survival curve showing 'DOI-free Survival Probability' over time in weeks.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
35
The chart uses a diagonal line to represent growth or accumulation of patient segments.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
37
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
46
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
54
The slide uses a process flow diagram to justify targeting C2. It contrasts this with other potential targets (labeled 1 and 2) and highlights the benefits of C2 inhibition.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
57
The slide presents clinical trial safety data for ARGX-117, highlighting that most adverse events are low grade and unrelated to the drug.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
60
The chart compares three dosing regimens (60mg/kg LD + 10mg/kg Q2W, 40mg/kg Q4W, 60mg/kg Q8W) against a 99% reduction threshold.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
62
The slide highlights the clinical burden and market opportunity for new therapies.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
63
The slide uses a numbered list format to explain a biological mechanism and clinical correlation.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
67
The slide uses a process flow diagram to illustrate the clinical trial stages.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit